160 related articles for article (PubMed ID: 35919127)
1. Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.
Brons M; Muller SA; Rutten FH; van der Meer MG; Vrancken AFJE; Minnema MC; Baas AF; Asselbergs FW; Oerlemans MIFJ
Eur Heart J Open; 2022 Mar; 2(2):oeac011. PubMed ID: 35919127
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
Briasoulis A; Lama N; Rempakos A; Theodorakakou F; Stamatelopoulos K; Dimopoulos MA; Kelekis N; Kastritis E
Curr Probl Cardiol; 2023 Apr; 48(4):101573. PubMed ID: 36586704
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
[TBL] [Abstract][Full Text] [Related]
4. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis.
Hosch W; Bock M; Libicher M; Ley S; Hegenbart U; Dengler TJ; Katus HA; Kauczor HU; Kauffmann GW; Kristen AV
Invest Radiol; 2007 Sep; 42(9):636-42. PubMed ID: 17700279
[TBL] [Abstract][Full Text] [Related]
5. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
Ioannou A; Patel RK; Razvi Y; Porcari A; Sinagra G; Venneri L; Bandera F; Masi A; Williams GE; O'Beara S; Ganesananthan S; Massa P; Knight D; Martinez-Naharro A; Kotecha T; Chacko L; Brown J; Rauf MU; Manisty C; Moon J; Lachmann H; Wechelakar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
Circulation; 2022 Nov; 146(22):1657-1670. PubMed ID: 36325894
[TBL] [Abstract][Full Text] [Related]
6.
Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
[TBL] [Abstract][Full Text] [Related]
8. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
9. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.
López-Sainz Á; Hernandez-Hernandez A; Gonzalez-Lopez E; Domínguez F; Restrepo-Cordoba MA; Cobo-Marcos M; Gómez-Bueno M; Hernandez-Perez FJ; Oteo JF; Mirelis JG; Cavero MA; Moñivas V; Mingo Santos S; de Haro-Del Moral FJ; Krsnik I; Salas C; Bornstein B; Briceño A; López JA; Vázquez J; Alonso-Pulpón L; Segovia J; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):149-158. PubMed ID: 32317158
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination.
Porcari A; Bussani R; Merlo M; Varrà GG; Pagura L; Rozze D; Sinagra G
Front Cardiovasc Med; 2021; 8():749523. PubMed ID: 34888361
[No Abstract] [Full Text] [Related]
11. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
[TBL] [Abstract][Full Text] [Related]
12. Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study.
Cicco S; Solimando AG; Buono R; Susca N; Inglese G; Melaccio A; Prete M; Ria R; Racanelli V; Vacca A
Life (Basel); 2020 Oct; 10(10):. PubMed ID: 33081052
[TBL] [Abstract][Full Text] [Related]
13. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
Rosenblum H; Masri A; Narotsky DL; Goldsmith J; Hamid N; Hahn RT; Kodali S; Vahl T; Nazif T; Khalique OK; Bokhari S; Soman P; Cavalcante JL; Maurer MS; Castaño A
Eur J Heart Fail; 2021 Feb; 23(2):250-258. PubMed ID: 32729170
[TBL] [Abstract][Full Text] [Related]
14. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.
Baggiano A; Boldrini M; Martinez-Naharro A; Kotecha T; Petrie A; Rezk T; Gritti M; Quarta C; Knight DS; Wechalekar AD; Lachmann HJ; Perlini S; Pontone G; Moon JC; Kellman P; Gillmore JD; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):69-80. PubMed ID: 31202744
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
16. Cardiac amyloidosis: in search of the ideal diagnostic tool.
Mavrogeni SI; Vartela V; Ntalianis A; Vretou R; Ikonomidis I; Tselegkidou M; Paraskevaidis I; Markousis-Mavrogenis G; Noutsias M; Rigopoulos A; Kolovou G; Kastritis E
Herz; 2021 Apr; 46(Suppl 1):9-14. PubMed ID: 31796976
[TBL] [Abstract][Full Text] [Related]
17. Current Challenges of Cardiac Amyloidosis Awareness among Romanian Cardiologists.
Adam R; Neculae G; Stan C; Jurcut R
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34066384
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
19. Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study.
Westin O; Butt JH; Gustafsson F; Schou M; Salomo M; Køber L; Maurer M; Fosbøl EL
JACC CardioOncol; 2021 Oct; 3(4):522-533. PubMed ID: 34729524
[TBL] [Abstract][Full Text] [Related]
20. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Aimo A; Merlo M; Porcari A; Georgiopoulos G; Pagura L; Vergaro G; Sinagra G; Emdin M; Rapezzi C
Eur J Heart Fail; 2022 Dec; 24(12):2342-2351. PubMed ID: 35509173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
